Literature DB >> 12543657

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.

Alison K Meagher1, Alan Forrest, Craig R Rayner, Mary C Birmingham, Jerome J Schentag.   

Abstract

Data obtained from 318 adult patients treated under the linezolid compassionate-use protocol were used to develop a population model of the pharmacokinetics of intravenous and oral linezolid. All of the patients received 600 mg of linezolid every 12 h, intravenously and/or orally. Blood samples (2 to 10 per patient; median, 4) were obtained and assayed for linezolid by high-performance liquid chromatography. These data and patient covariates were modeled by iterative two-stage analysis, and model discrimination was done by Akaike's information criterion. Of the patient covariates considered (age, sex, ideal body weight, baseline serum albumin, hepatic or renal dysfunction, underlying malignancy, organ transplantation, surgical status, global severity of illness, site of infection, route of administration, and location of care [intensive-care unit, general floor, or outpatient]), only normalized creatinine clearance (CL(CR)) and body weight explained significant portions of the variance and were incorporated into the pharmacokinetic model. The final model included central and peripheral compartments with parallel capacity-limited (nonrenal) and first-order (renal [CL(R)]) clearances. Volumes and clearances were normalized to the ideal body weight, and CL(R) was modeled as proportional to CL(CR). Compared to previously studied adult volunteers, intrinsic clearance was approximately 60% higher and the maximum rate of metabolism was twice as high in these debilitated patients, resulting in lower area under the time-concentration curve (AUC) values (P < 0.001). The derived 24-h AUC, averaged over the first 7 days of treatment, ranged between 57 and 871 (median, 191) micro g/ml. 24 h. Despite these variations, linezolid provided high rates of clinical cure, as well as microbiological success, in the patients treated in the compassionate-use program. The mechanism(s) of these pharmacokinetic differences is unknown and requires further mechanistic study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543657      PMCID: PMC151778          DOI: 10.1128/AAC.47.2.548-553.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

3.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

4.  In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Authors:  R N Jones; D M Johnson; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.

Authors:  D R Ashtekar; R Costa-Periera; T Shrinivasan; R Iyyer; N Vishvanathan; W Rittel
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Nov-Dec       Impact factor: 2.803

7.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Authors:  Mary C Birmingham; Craig R Rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

  7 in total
  47 in total

1.  Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.

Authors:  Rebecca A Keel; Andre Schaeftlein; Charlotte Kloft; J Samuel Pope; R Frederic Knauft; Marianne Muhlebach; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.

Authors:  Piergiorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

5.  Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.

Authors:  Ryan L Crass; Pier Giorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

6.  Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.

Authors:  Bryan McGee; Reynaldo Dietze; David Jamil Hadad; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; W Henry Boom; Moises Palaci; John L Johnson; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

7.  Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Authors:  Yasuhiro Tsuji; Nicholas H G Holford; Hidefumi Kasai; Chika Ogami; Young-A Heo; Yoshitsugu Higashi; Akiko Mizoguchi; Hideto To; Yoshihiro Yamamoto
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

8.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

9.  Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.

Authors:  Amira A Bhalodi; Pavlos K Papasavas; Darren S Tishler; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.